Life Sciences Financing Roundup: $5.7B Buyout, Juvisé Refinancing, Biotech IPO
A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.
The life sciences sector saw significant financing activity this week. A global investment firm has agreed to acquire a medical device manufacturer in an all-cash transaction valued at approximately $5.7 billion, offering shareholders about $127 per share, a 51% premium to the stock price before a strategic review was announced in April. Juvisé Pharmaceuticals secured a $652 million refinancing, and a biotech company raised $289 million in an upsized Nasdaq offering.
The medical device manufacturer believes going private will provide greater flexibility and long-term capital to expand its contract development and manufacturing business, including investments in capacity, technology and innovation. The deal is expected to close by year-end, subject to shareholder and regulatory approvals.
Juvisé's refinancing, in partnership with Hayfin Capital Management, includes €400 million ($474.5 million) for repayment of existing debt and €150 million ($177.9 million) as a capital expenditure facility to support M&A activity. The refinancing is said to bolster Juvisé's financial flexibility, extend its debt maturity profile, and provide additional resources to support future growth initiatives. Juvisé will prioritize assets with strong medical benefits in indications commonly treated by specialist doctors, focusing on neurology, gastroenterology, and oncology. The firm previously acquired global commercial rights (excluding the US and Canada) to Ponvory (ponesimod) from Actelion Pharmaceuticals in March 2024, worldwide rights to Pylera from AbbVie in 2022, and cancer drugs Arimidex (anastrozole) and Casodex (bicalutamide) from AstraZeneca six years ago.
The biotech company, focused on immune-mediated diseases, raised $289 million in an upsized Nasdaq offering (17 million shares at $17/share), marking the third consecutive week of biotech IPOs. Proceeds will fund the company's pipeline of three I&I drug candidates and its multispecific antibody platform, designed to create biologics that bind multiple targets for potentially stronger and longer-lasting efficacy. The company expects its lead candidate to enter Phase 2 in the first half of 2027, with two additional programs advancing into Phase 1 around the same time.
Barcelona-based Pharmacelera raised €6 million ($7.1 million) in a financing round led by Heran Partners, with participation from Clave Capital, Inveready, and Bio&Tech Smart Capital. The funding will allow Pharmacelera to advance its QaiM platform and establish a permanent US presence, starting with a team in Boston, Massachusetts. The company combines quantum mechanics and AI with an aim to transform drug discovery and has already demonstrated its scalability and commercial viability, with repeat business from pharmaceutical companies and biotechs in Europe and the US.
Separately, the Medicines and Healthcare products Regulatory Agency, working with NHS England, published guidance clarifying how existing medical device regulations apply to ambient voice technology (AVT) products used in health and care settings. The guidance confirms that AVT products intended to support diagnosis, treatment or prevention, or those that take automated actions without clinician review, fall within medical device regulation and must meet relevant safety and performance requirements. In addition, a major clinical research organization entered a multi-year partnership to integrate AI across its clinical trial operations, enhancing site selection, study feasibility, protocol design, enrollment forecasting and risk detection, with the goal of improving trial efficiency and addressing bottlenecks such as patient enrollment delays.
China's booming biotech sector is driving a sharp shortage of laboratory monkeys used in preclinical drug testing, causing prices to surge to as much as $26,000 per monkey, nearly double a year ago. The shortage is fueled by strong demand for biologics, antibody-drug conjugates, bispecifics and other next-generation therapies that require primate safety studies before entering clinical trials. Some studies are facing delays of four to 10 months as companies compete for limited primate capacity.